<DOC>
	<DOCNO>NCT01611259</DOCNO>
	<brief_summary>This open label , phase II study evaluate capacity Rituximab ( Mabthera® ) plus Lenalidomide ( Revlimid® ) induce objective response patient Mucosa Associated Lymphoid Tissue ( MALT ) lymphoma present measurable disease .</brief_summary>
	<brief_title>Rituximab Plus Lenalidomide Patients With Mucosa Associated Lymphoid Tissue</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<criteria>Inclusion Criteria select : Histologically verify diagnosis MALT lymphoma localization Measurable disease upon diagnosis first great relapse local therapy , prior chemotherapy orHPeradication . In addition , also patient gastric MALTlymphoma judge refractory HPeradication minimum followup 12 month successfulHPeradication include study . Patients gastric MALT lymphoma evidence HPinfection may enrol immediately Ann Arbor Stage IIV In case prior treatment Rituximab , presence CD20 lymphoma cell must demonstrate inclusion trial . ECOG performance status 0,1 2 Patient must able take aspirin daily prophylactic anticoagulation ( patient intolerant ASA may use warfarin low molecular weight heparin Exclusion Criteria select : Lymphoma histology MALT lymphoma MALT lymphoma diffuse large cell lymphoma ( `` high grade lymphoma '' ) component Use investigational agent within 28 day prior initiation treatment lenalidomide History malignancy squamous cell carcinoma , basal cell carcinoma skin carcinoma situ cervix within last 5 year Major surgery , diagnostic surgery , within last 4 week Evidence CNS involvement A history uncontrolled seizure , central nervous system disorder psychiatric disability judge investigator clinically significant adversely affect compliance study drug Severe peripheral polyneuropathy Clinically significant cardiac disease myocardial infarction within last 6 month Known hypersensitivity thalidomide lenalidomide rituximab</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>MALT Lymphoma</keyword>
	<keyword>Lenalidomide</keyword>
	<keyword>Rituximab</keyword>
</DOC>